Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
C4 Therapeutics Director Steven L. Hoerter received a stock option grant on June 18, 2025 to purchase 35,500 shares of common stock at an exercise price of $1.44 per share.
Key details of the stock option:
- The option expires on June 17, 2035
- Vesting occurs at the earlier of June 18, 2026 or the next annual stockholders' meeting
- Vesting is contingent on continued Board service
- The grant was reported via Form 4 filing, indicating changes in beneficial ownership
This equity compensation aligns with standard director compensation practices and serves to align the director's interests with shareholders. The relatively low exercise price reflects the company's current market conditions.